Pyxis Oncology (PYXS) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vogenx is the larger company by market cap ($259.8 million vs $237.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PYXS | VOGX |
|---|---|---|
| Share price | $1.99 | $17.49 |
| Market cap | $237.72M | $259.82M |
| 1-day change | -1.00% | +8.23% |
| YTD return | +73.04% | — |
| 1-year return | -31.62% | — |
| 5-year return | -83.09% | — |
| EPS (TTM) | $-1.40 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.55 | $38.41 |
| 52-week low | $1.03 | $12.95 |
| Distance from 52-week high | -64.14% | -54.46% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +335.68% | +214.47% |
| Average volume | 1.25M | 188.79K |
| Shares outstanding | 119.46M | 14.86M |
| Employees | 56 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
PYXS vs VOGX FAQ
Which is bigger, Pyxis Oncology or Vogenx?
Vogenx (VOGX) is larger, with a market capitalization of $259.82M compared with $237.72M for Pyxis Oncology (PYXS).
Are Pyxis Oncology and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.